The purpose of this study was to monitor the dose modifying effect of supplemental dietry beta-carotene on the progression of the oral mucosal reaction and treatment outcome during an intensive course of synchronous radiation and chemotherapy. Table  I) .
The difference in the range of acute mucosal reactions recorded in the two groups of patients is shown in Table II . When analysed in terms of patient weeks a significantly (P < 0.025) less severe reaction was measurable in the patients receiving supplemental beta-carotene. The time sequence over which the severe reactions developed is depicted in Figure 1 .
Remission rate was not significantly different in the two groups of patients. At the completion of treatment 8/20 (40%) patients had complete remission and 3/20 patients had partial remission (>50% reduction of the greatest diameter). Long term follow up at 29 to 45 months (mean 36) showed local tumour control was sustained in 5 patients of whom Of those patients who failed treatment all died with locoregional disease. They comprised 6 patients from each of the study and control arms. The mean tumour-free period was 5 and 4 months and the survival period 11 and 12 months respectively.
Late responding tissue changes were limited to mild oedema and induration of the soft tissues of the neck in all 5 surviving patients. Two patients with mandibular infiltration had non-healing and progressive disease.
Recent years have seen a considerable interest in the role of vitamin A in the induction and treatment of cancer. Numerous synthetic derivatives varying in mode of action, efficacy and toxicity, have shown significant therapeutic benefits when used as an adjuvant to radiotherapy and chemotherapy in animal tumour systems (Seifter et al., 1983) . These compounds have however been little used in clinical oncology. This is probably related to the severe toxicity experienced at effective dose levels and because of sporadic laboratory reports of tumour growth enhancement by vitamin A administration (Levij & Polliack, 1969) .
The pro-vitamin A (beta-carotene) when used as an adjunct to radiotherapy in the treatment of transplantable adenocarcinoma in mice (Seifter et al., 1983) significantly improved tumour reduction, survival and wound healing. This anti-tumour effect was more pronounced with betacarotene supplementation than with vitamin A. In addition those animals receiving such compound showed diminished local and whole body radiation toxic effects. Beta carotene is said to be the most efficient quencher of singlet oxygen thus far known to man and is naturally protective against the damaging effects of ultra violet irradiation in plants undergoing photosynthesis (Foote, 1976) . This and the fact that its use in man is reportedly safe (WHO, 1974) prompted the author to utilise large doses of supplemental beta-carotene during a course of intensive combination chemotherapy and radiotherapy for advanced head and neck epidermoid tumours.
Although the small number of patients studied militates against the statistical validity of the results reported, it does suggest that a protective action of beta-carotene is exerted on the mucosal membrane within the radiation fields used.
This trend is not reflected in the observations made on late responding tissue changes. There is likewise no difference in tumour control rates or survival amongst the patients studied. This is notwithstanding the reported inhibitory effect of both vitamin A and beta-carotene on tumour growth in experimental systems which has been well documented and reviewed (Lotan, 1980; Mills, 1983) .
The above results and freedom from toxic side effects suggest that beta-carotene should be further studied as an adjunct to radiation therapy of tumours.
